Press Room

AAPS 2021 PharmSci 360

Start
Sunday, October 17, 2021 - 00:00
End
Wednesday, October 20, 2021 - 00:00
Location: Philadelphia, USA
Booth Number: 1202
fully integrated solution provider for inhalation | Hovione

We are ready to safely return to AAPS PharmSci 360 in Philadelphia and we look forward to seeing you.

 

Schedule a meeting at the Hovione's booth (#1202) or online

Schedule a meeting button | Hovione

 

HOVIONE PRESENTATIONS AT AAPS

Join Hovione Scientists in their virtual oral presentations and poster abstracts and find out more about their latest research and innovation.

maria paisana Analytical Development Scientist | Hovione

 

Maria Paisana - Senior Analytical Scientist, Analytical Development Group

Presentation: Make it Flow: Can Ring Shear Tester Predict Flowability Through Hoppers?
Poster: Ring Shear Tester: The importance of Shear and Wall Friction Methodology for Arching Tendency Predictions

 

 

 
Luis Sobral Fellow Scientist R&D | Hovione

 

Luís Sobral - Fellow Scientist, R&D
Presentation: Modeling Chemical Reactions with Quantum Mechanics

 

Ricardo Gonçalves R&D Analytical Development | Hovione

Ricardo Gonçalves - Analytical Scientist, R&D Analytical Development
Presentation: Understanding Dry Powder Inhalers Formulations: Role of Surface Polarity of lactose mixtures

 

Beatriz Noriega-Fernandes Inhalation and Advanced Drug Delivery R&D | Hovione

 

Beatriz Noriega-Fernandes - Scientist, Inhalation and Advanced Drug Delivery Group, R&D
Poster: Spray-Dried Composite Formulation Containing DSPC for Lung Sustained Release

 

 
Luis Sousa R&D Analytical Development | Hovione

 

Luís Sousa - Senior Analytical Scientist, R&D Analytical Development
Poster: Evaluation of the Relaxation State of Amorphous Itraconazole Using Solution Calorimetry

 

From feasibility to commercial: Integrated Dry Powder Inhalation solutions to help bring inhaled medicines to patients

 
 

Hovione offers Customized high-performance APIs, Particle Engineering and Formulation along with a full range of highly specialized, innovative inhalation Devices. Our motto is Everything for Inhalation meaning great People, great Science and Technology combined with a strong Quality and Safety culture.

 

 

Let’s discuss your project together. 

 

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024